Last reviewed · How we verify

Diltiazem Hydrochloride 2% Cream — Competitive Intelligence Brief

Diltiazem Hydrochloride 2% Cream (Diltiazem Hydrochloride 2% Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Dermatology / Pain Management.

phase 3 Calcium channel blocker L-type calcium channels Dermatology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Diltiazem Hydrochloride 2% Cream (Diltiazem Hydrochloride 2% Cream) — Ventrus Biosciences, Inc. Diltiazem is a calcium channel blocker that reduces smooth muscle contraction and improves blood flow when applied topically to affected tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diltiazem Hydrochloride 2% Cream TARGET Diltiazem Hydrochloride 2% Cream Ventrus Biosciences, Inc phase 3 Calcium channel blocker L-type calcium channels
Amlodipine/Olmesartan Amlodipine/Olmesartan Radboud University Medical Center marketed Calcium channel blocker / Angiotensin II receptor blocker combination L-type calcium channels (amlodipine); AT1 angiotensin II receptor (olmesartan)
Rate-control therapy Rate-control therapy Our Lady of the Lake Hospital marketed AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides) AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)
losartan/amlodpine losartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB) Angiotensin II receptors (AT1) and L-type calcium channels
Perindopril plus Amlodipine Perindopril plus Amlodipine University of Abuja marketed ACE inhibitor + Calcium channel blocker combination ACE (angiotensin-converting enzyme) and L-type calcium channels
Nitrendipine/Atenolol Nitrendipine/Atenolol Shanghai Jiao Tong University School of Medicine marketed Calcium channel blocker / Beta-blocker combination L-type calcium channels; Beta-1 adrenergic receptor
ACEI/CCB ACEI/CCB Shanghai Jiao Tong University School of Medicine marketed Antihypertensive combination (ACEI/CCB) Angiotensin-converting enzyme; L-type calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diltiazem Hydrochloride 2% Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/diltiazem-hydrochloride-2-cream. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: